Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06564038 · ClinicalTrials.gov registry record · Phase 1

A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies

A Phase 1 study of Mantle Cell Lymphoma and Small Lymphocytic Lymphoma, sponsored by AstraZeneca.

Recruiting
Registry status
Phase 1
Development phase
276
Enrollment target
20
Study locations

NCT06564038 is a Phase 1 study of Mantle Cell Lymphoma and Small Lymphocytic Lymphoma that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 276 participants, above the 101-participant average among 102 other Mantle Cell Lymphoma trials with a reported enrollment target (173% higher). The trial reports 20 study locations across 10 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06564038, a Phase 1 study of Mantle Cell Lymphoma and Small Lymphocytic Lymphoma, is actively recruiting participants, sponsored by AstraZeneca.

RECRUITING
Registry status
Phase 1
Development phase
276 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to assess the safety and efficacy of AZD0486 administered as monotherapy or in combination with other anticancer agents in participants with hematological malignancies.

Conditions Studied

Mantle Cell Lymphoma Small Lymphocytic Lymphoma Large B-cell Lymphoma B-Cell Non-Hodgkin Lymphoma Chronic Lymphocytic Leukaemia

Interventions

  • DRUG Cyclophosphamide
  • DRUG Rituximab
  • DRUG Vincristine
  • DRUG AZD0486
  • DRUG Prednisone (or equivalent)

Study Locations (20)

Other

  • Research Site - Heidelberg
  • Research Site - Melbourne
  • Research Site - Nedlands
  • Research Site - Beijing
  • Research Site - Guangzhou
  • Research Site - Jinan
  • Research Site - Tianjin

New Jersey

  • Research Site - Hackensack
  • Research Site - New Brunswick

New York

  • Research Site - New York
  • Research Site - New York

North Carolina

  • Research Site - Charlotte
  • Research Site - Charlotte

Pennsylvania

  • Research Site - Philadelphia
  • Research Site - Pittsburgh

Massachusetts

  • Research Site - Boston

Ohio

  • Research Site - Columbus

Oregon

  • Research Site - Portland

Trial Details

FieldValue
Enrollment Target 276 participants
Start Date 2025-01-30
Est. Completion 2028-02-28
Phase Phase 1

Sponsor

AstraZeneca

1,285 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06564038

The ClinicalTrials.gov registry entry for NCT06564038 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 276 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 101-participant average among 102 other Mantle Cell Lymphoma trials with a reported enrollment target (173% higher). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 5 conditions, with Mantle Cell Lymphoma appearing as the primary indexed condition, and to 5 interventions - of which Cyclophosphamide is the first listed.

NCT06564038 reports 20 study locations spanning 10 distinct geographic areas - top geographies include Other, New Jersey, New York.

Frequently Asked Questions

What is clinical trial NCT06564038 about?

NCT06564038 is a clinical study titled "A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies". The purpose of this study is to assess the safety and efficacy of AZD0486 administered as monotherapy or in combination with other anticancer agents in participants with hematological malignancies.

What is the current status of trial NCT06564038?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 276 participants. The study started on 2025-01-30. Estimated completion is 2028-02-28.

What conditions does trial NCT06564038 study?

This clinical trial studies the following conditions: Mantle Cell Lymphoma, Small Lymphocytic Lymphoma, Large B-cell Lymphoma, B-Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukaemia.

What interventions are being tested in trial NCT06564038?

The interventions under investigation include: Cyclophosphamide (DRUG), Rituximab (DRUG), Vincristine (DRUG), AZD0486 (DRUG), Prednisone (or equivalent) (DRUG).

Who is sponsoring clinical trial NCT06564038?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06564038 being conducted?

This trial has 20 study locations across Massachusetts, New Jersey, New York, North Carolina, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Mantle Cell Lymphoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Mantle Cell Lymphoma

All registered trials for this condition

Small Lymphocytic Lymphoma

All registered trials for this condition

Massachusetts

All trials with a study site in Massachusetts

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.